Aim To evaluate the impact of relevant patient‐level characteristics on the efficacy and safety
of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials and …

Aims SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study,
investigated once‐weekly semaglutide in patients with type 2 diabetes (T2D) in routine …

Background Despite a broad range of pharmacological options for the treatment of type 2
diabetes, optimum glycaemic control remains challenging for many patients and new …

Abstract Aims SURE Switzerland (NCT03631186) investigated real-world once-weekly (OW)
semaglutide use in adults with type 2 diabetes (T2D). Methods This multicentre, prospective …

Abstract Aim PIONEER REAL Canada examined real‐world clinical outcomes associated
with the use of once‐daily oral semaglutide in adults with type 2 diabetes. Materials and …

Aim To investigate once‐weekly (OW) semaglutide, a glucagon‐like peptide‐1 receptor
agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) in routine clinical practice …

Context Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established
in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 …

Aim To investigate the impact of treatment with once‐weekly subcutaneous semaglutide, a
glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), for up to 2 years in people with type 2 …

Aims To investigate real‐world short‐term clinical outcomes in adults with type 2 diabetes
(T2D) who initiated semaglutide in a specialist endocrinology practice in Canada. Materials …

Oral semaglutide is the first oral glucagon‐like peptide‐1 receptor agonist for the treatment
of type 2 diabetes, and showed significant benefits in glycaemic control and weight …